![Figure 1, Literature flow - Supplemental Project to Assess the Transparency of Reporting Requirements: Omega-3 Fatty Acids and Cardiovascular Disease - NCBI Bookshelf Figure 1, Literature flow - Supplemental Project to Assess the Transparency of Reporting Requirements: Omega-3 Fatty Acids and Cardiovascular Disease - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK475902/bin/resultsf1.jpg)
Figure 1, Literature flow - Supplemental Project to Assess the Transparency of Reporting Requirements: Omega-3 Fatty Acids and Cardiovascular Disease - NCBI Bookshelf
![FIGURE 8. [Steps in Vaccine Development]. - The Scientific Future of DNA for Immunization - NCBI Bookshelf FIGURE 8. [Steps in Vaccine Development]. - The Scientific Future of DNA for Immunization - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK563532/bin/AAMCol.31May1996.fig08.jpg)
FIGURE 8. [Steps in Vaccine Development]. - The Scientific Future of DNA for Immunization - NCBI Bookshelf
![Figure 2, Summary of the Risk of Bias Assessments for the Randomized Controlled Trials - Drugs for Chronic Hepatitis C Infection: Clinical Review - NCBI Bookshelf Figure 2, Summary of the Risk of Bias Assessments for the Randomized Controlled Trials - Drugs for Chronic Hepatitis C Infection: Clinical Review - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK350737/bin/tr0008f2.jpg)
Figure 2, Summary of the Risk of Bias Assessments for the Randomized Controlled Trials - Drugs for Chronic Hepatitis C Infection: Clinical Review - NCBI Bookshelf
![Figure 2, Overview of Key Clinical Trials for Telotristat - Clinical Review Report: Telotristat (Xermelo) - NCBI Bookshelf Figure 2, Overview of Key Clinical Trials for Telotristat - Clinical Review Report: Telotristat (Xermelo) - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK546783/bin/cl4f2.jpg)
Figure 2, Overview of Key Clinical Trials for Telotristat - Clinical Review Report: Telotristat (Xermelo) - NCBI Bookshelf
![Figure 2, Summary of Evidence Search and Selection - Screening for Atrial Fibrillation With Electrocardiography: An Evidence Review for the U.S. Preventive Services Task Force - NCBI Bookshelf Figure 2, Summary of Evidence Search and Selection - Screening for Atrial Fibrillation With Electrocardiography: An Evidence Review for the U.S. Preventive Services Task Force - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK525516/bin/ch3f1.jpg)
Figure 2, Summary of Evidence Search and Selection - Screening for Atrial Fibrillation With Electrocardiography: An Evidence Review for the U.S. Preventive Services Task Force - NCBI Bookshelf
![Figure 3, Study Design of the ATLAS Trial - Clinical Review Report: Cabotegravir Tablets, Cabotegravir Extended-Release Injectable Suspension, and Rilpivirine Extended-Release Injectable Suspension (Vocabria, Cabenuva) - NCBI Bookshelf Figure 3, Study Design of the ATLAS Trial - Clinical Review Report: Cabotegravir Tablets, Cabotegravir Extended-Release Injectable Suspension, and Rilpivirine Extended-Release Injectable Suspension (Vocabria, Cabenuva) - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK566702/bin/cl4f3.jpg)
Figure 3, Study Design of the ATLAS Trial - Clinical Review Report: Cabotegravir Tablets, Cabotegravir Extended-Release Injectable Suspension, and Rilpivirine Extended-Release Injectable Suspension (Vocabria, Cabenuva) - NCBI Bookshelf
![Figure 3, Compounds in Clinical Trials for Chagas Disease - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf Figure 3, Compounds in Clinical Trials for Chagas Disease - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK56242/bin/ml158f3.jpg)
Figure 3, Compounds in Clinical Trials for Chagas Disease - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf
![Figure 2, Schematic Showing the Design of the ORATORIO Trial - Clinical Review Report: Ocrelizumab (Ocrevus) - NCBI Bookshelf Figure 2, Schematic Showing the Design of the ORATORIO Trial - Clinical Review Report: Ocrelizumab (Ocrevus) - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK533357/bin/cl3f2.jpg)
Figure 2, Schematic Showing the Design of the ORATORIO Trial - Clinical Review Report: Ocrelizumab (Ocrevus) - NCBI Bookshelf
![Selection of Included Studies - The Use of Antivirals for Influenza Prophylaxis: A Review of the Clinical Effectiveness - NCBI Bookshelf Selection of Included Studies - The Use of Antivirals for Influenza Prophylaxis: A Review of the Clinical Effectiveness - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK519830/bin/app1f1.jpg)
Selection of Included Studies - The Use of Antivirals for Influenza Prophylaxis: A Review of the Clinical Effectiveness - NCBI Bookshelf
GitHub - NCBI-Hackathons/CTEligible: Use machine learning to find patterns of similar eligibility protocol criteria for clinical trials
![Figure 4.1-1, Structure of darapladib, a GlaxoSmithKline drug in phase III clinical trials for the treatment of atherosclerosis - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf Figure 4.1-1, Structure of darapladib, a GlaxoSmithKline drug in phase III clinical trials for the treatment of atherosclerosis - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK133433/bin/ml256f12.jpg)
Figure 4.1-1, Structure of darapladib, a GlaxoSmithKline drug in phase III clinical trials for the treatment of atherosclerosis - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf
![Figure 3, Compounds in Clinical Trials for Chagas Disease - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf Figure 3, Compounds in Clinical Trials for Chagas Disease - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK55071/bin/ml157f3.jpg)
Figure 3, Compounds in Clinical Trials for Chagas Disease - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf
![Figure 2, Summary of Evidence Search and Selection - Screening for Prediabetes and Type 2 Diabetes Mellitus: An Evidence Review for the U.S. Preventive Services Task Force - NCBI Bookshelf Figure 2, Summary of Evidence Search and Selection - Screening for Prediabetes and Type 2 Diabetes Mellitus: An Evidence Review for the U.S. Preventive Services Task Force - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK574062/bin/ch3f1.jpg)
Figure 2, Summary of Evidence Search and Selection - Screening for Prediabetes and Type 2 Diabetes Mellitus: An Evidence Review for the U.S. Preventive Services Task Force - NCBI Bookshelf
![ClinicalTrials.gov updates the PRS Guided Tutorials, step-by-step instructions for data providers - NCBI Insights ClinicalTrials.gov updates the PRS Guided Tutorials, step-by-step instructions for data providers - NCBI Insights](https://i0.wp.com/ncbiinsights.ncbi.nlm.nih.gov/wp-content/uploads/2021/03/Picture1.png?resize=437%2C158&ssl=1)
ClinicalTrials.gov updates the PRS Guided Tutorials, step-by-step instructions for data providers - NCBI Insights
![Figure B, Literature flow diagram - Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings - NCBI Bookshelf Figure B, Literature flow diagram - Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK208583/bin/fmf2.jpg)